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Rapid developments in the field ofmedical imaging have openednewavenues for the use of positron emitting labeledmicroparticles.
The radioisotope used in our research was 68Ga, which is easy to obtain from a generator and has good nuclear properties for
PET imaging.Methods. Commercially available macroaggregated albumin (MAA) microparticles were suspended in sterile saline,
centrifuged to remove the free albumin and stannous chloride, relyophilized, and stored for later labeling with 68Ga. Labeling
was performed at different temperatures and times. 68Ga purification settings were also tested and optimized. Labeling yield and
purity of relyophilized MAA microparticles were compared with those that were not relyophilized. Results. MAA particles kept
their original size distribution after relyophilization. Labeling yield was 98% at 75∘C when a 68Ga purification system was used,
compared to 80% with unpurified 68Ga. Radiochemical purity was over 97% up to 4 hours after the labeling. The relyophilized
MAA and labeling method eliminate the need for centrifugation purification of the final product and simplify the labeling process.
Animal experiments demonstrated the high in vivo stability of the obtained PET agent withmore than 95% of the activity remaining
in the lungs after 4 hours.
1. Introduction
Starting in 1964, several efforts have been made to find an
agent for perfusion and embolization [1, 2]. A lyophilized
kit for the preparation of 99mTc-MAA was created in 1974
for Single Photon Emission Tomography (SPECT) imaging.
With the arrival of Positron Emission Tomography (PET)
the formulation of an analogue drug with a positron emitter
was needed. Among the available PET isotopes 68Ga is easily
obtained from its parent nuclide 68Ge by chromatographic
column separation with different inorganic exchangers. The
long lived parent allows the construction of a generator that
can last up to two years [3] compared to a 99mTc/99Mo gener-
ator which lasts only for 1-2 weeks.MAAwas first successfully
labeled with 68Ga in 1989 [4] but never used, probably due
to unreliability of the existing 68Ge/68Ga generators and low
availability of PET imaging cameras. Revived interest has
been shown recently [5, 6], and the first PET lung perfusion
studies in humans have been performed [7, 8].
Selective internal radiation treatment (SIRT), a technique
used to treat metastatic liver cancer, could also benefit from
a PET perfusion tracer. During the planning stage, a 99mTc-
MAA perfusion scan is performed to assess the allocation
in lung and gastrointestinal tract. It is also used to calculate
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tumor to normal liver allocation ratio [9]. The distribution
acts as a predictor of the treatment safety and effectiveness.
A PET perfusion agent (e.g., 68Ga-MAA) could provide
valuable, quantifiable information to calculate precise doses,
which could potentially improve the treatment outcome.
Initial work with 68Ga-MAA for SIRT planning has already
been performed [10].
All reported 68Ga labeling of MAA has been done using
a commercial MAA kit for 99mTc (mainly Pulmolite kit, no
longer on the market). All kits contain approximately 100 𝜇g
stannous chloride and free albumin; hence the particles need
to be washed with saline before 68Ga labeling.Themaximum
reported labeling yield using the Pulmolite kit is around
80% [5]. Elimination of the free 68Ga via centrifugation is
therefore necessary. The purification process is also required
to eliminate traces of the long half-life 68Ge that are eluted
from the generator (required only if 68Ge ≥ 0.001% of
the 68Ge/68Ga generator activity or 0.5𝜇Ci for a 50mCi
generator). A new 68Ga specific MAA lyophilized kit is
needed for labeling. Further, it needs to be combined with a
prepurification system that assures prior elimination of 68Ge
traces and provides pure, preconcentrated 68Ga for
labeling.
2. Materials and Methods
2.1. MAA Lyophilized Kit Preparation. Macroaggregated
albumin (MAA) was obtained from Triad Isotopes (Drax-
Image kit). The content was reconstituted with 0.9% saline
solution, separated into two 15mL centrifuge tubes (to match
the original 4 ⋅ 106 number of particles present in the
Pulmolite kit for comparison purposes), centrifuged (Eppen-
dorf, Germany), and the supernatant discarded (“washed
MAA”) [4]. The particles were then relyophilized overnight
and stored for labeling (“relyophilized MAA”). Size and
morphology analysis was performed on reconstituted MAA
using an optical microscope (Micromaster, Fisher-Sci, USA)
and a hemacytometer (Reichert, USA) before and after
relyophilization.
2.2. 68Ge/68Ga Radioisotopic Generator. The 68Ge/68Ga gen-
erator used was the 50mCi IGG-100 (Eckert & Ziegler,
Germany), based on the TiO
2
resin technology, eluted with
5mL of 0.1M ultrapure HCl (Sigma-Aldrich, USA) solution.
2.3. Purification System. A combination of chromatographic
exchange resins was used [11]. Two Luer-fitting column
beds were prepared. First, 40 ± 10mg of AG-50Wx8 cation
exchange (Eichrom, USA) column is connected to a three-
way stopcock. Next, 15 ± 5mg of UTEVA anion exchange
(Eichrom, USA) resin in a column is positioned. Finally,
another three-way stopcock is located at the end. The system
was designed to be used in four simple steps: elution (from the
generator, 5mL of 0.1M HCl); cleaning (1mL of 0.1M HCl);
purification (1mL of 5M HCl); extraction (1mL of Millipore
Water) (Figure 2).
2.4. MAA Labeling. Both, washed MAA and relyophilized
MAA, were labeled (using the original Green’s method [4,
5]) with either purified or unpurified 68Ga solution. The
unpurified 68Ga solution was obtained directly from the
generator (5mL, pH = 1, A ≈ 10mCi). The purified 68Ga
elution (1mL, pH = 0.6, A ≈ 10mCi) was obtained from the
purification system. Both were buffered using 0.3mL of 3N
ultrapure sodium acetate (Sigma-Aldrich, USA).The solution
was added to the 15mL centrifuge tube containing the MAA.
Labeling was performed using a thermomixer with a heating
block for 15mL centrifuge tubes and stirring at 750 rpm
(Eppendorf, Germany). Labeling temperature was 25 (room
temperature), 50, 75, and 95 degrees Celsius. Labeling time
was set at 15 minutes based on previous reports of MAA-
68Ga labeling kinetics [4, 5]. Particles were separated from the
supernatant by centrifugation. The particles and supernatant
were measured separately using an Atomlab 100 dose calibra-
tor (Biodex, USA). Final particles were resuspended in 5mL
saline solution with a vortex mixer (Fisher-Sci, USA).
2.5. Animal Experiments. Sprague Dawley rats (200–225
grams, 2 per time point) were obtained from Harlan Lab-
oratories (Harlan, USA). Animals were weighed before the
procedure and anesthetized using an Ohmeda Isotec 3 isoflu-
rane vaporizer (GE Healthcare, USA). Isoflurane levels were
kept ≤3% at all times. Once completely anesthetized, animals
were restrained in the supine position and a torso X-Ray
was obtained (Belmont Acuray 071A, USA). Later, 100𝜇L of
the labeled MAA (8,000–10,000 particles) with an activity
ranging from 50 to 100 𝜇Ci (1.85–3.7MBq) was injected
through the lateral tail vein. Animals were euthanized at 2
or 4 hours. For either time points their lungs, liver, spleen,
heart, kidneys, ribs, and 0.2mL of blood and urine were
collected, weighed, and activitymeasured using a Cobra 5000
well counter (Packard, USA). Uncollimated autoradiography
images (in the unaltered supine position the X-Ray was
obtained) were also taken at 1, 2, 3, and 4 hours (Packard
Phosphorimager, Perkin Elmer, USA). Free 68Gawas injected
as a control. Additionally, imaging and organ collection were
also performed with 99mTc-MAA and reduced Na 99mTcO
4
(sodium pertechnetate) for comparison purposes. 99mTc-
MAAandNa 99mTcO
4
were purchased from a local pharmacy
(Triad Isotopes, USA). Approximately 5mCi of sodium
pertechnetate in 5mL of saline (pH ≈ 5.5) was reduced with
100 𝜇g of stannous chloride (Sigma-Aldrich, USA) before
injection. The obtained X-Rays and the autoradiography
images were superimposed to provide anatomical and func-
tional data.
3. Results and Discussion
3.1. MAA Relyophilization. The elimination of the excess free
albumin is a necessary step prior to successful labeling with
68Ga (“washed MAA”) [4, 5]. Resuspension of the particles
was fast using a vortex mixer; manual shaking of the vial
was also efficient. Relyophilization of the MAA did not
change either the particle’s size distribution or morphology
(Figure 1).
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Figure 1: MAA microscope images, (a) from original unmodified MAA kit and (b) from relyophilized MAA.
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Figure 2: Purification System Setup.
3.2. Purification System. The assembly of the purification
system is simple and easy to use (Figure 2).
The optimized and simple four-step purification process
is as follows. (1) Elution of the generator using a 0.1M HCl
solution. During this step the gallium is trapped with most
of the metal impurities in the cation exchanger. Most of the
68Ge contamination is removed in this step. (2) Cleaning
is performed with one extra mL of 0.1M HCl through the
syringe dock to remove the excess solution coming from
the generator. One mL of air is then vented to the system.
(3) Purification is performed with slow elution using 1mL
of 5M HCl. The Ga3+ forms a GaCl
4
− complex so it is
released from the cation exchanger and absorbed onto the
anion exchanger. One mL of air is also used to vent the
system. All the metal impurities are eliminated in this step
(especially Fe, Ti, and Zn). (4) Extraction is done using 1mL
of Millipore water in which the gallium complex is destroyed
and released from the anion exchanger into the labeling vial.
One mL of air is pushed through the system to remove
most of the 68Ga (Figure 3).The purification system retrieves
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Figure 3: 68Ga recovery and 68Ge elimination during the purifica-
tion process.
approximately 85% of the eluted gallium activity after 10
minutes of processing. It provides pure, preconcentrated 68Ga
in slightly acidic solution that is buffered by adding 0.3mL of
3N ultrapure sodium acetate [11]. All the 68Ge is eliminated
in the process; consequently radio-nuclide impurities are
eliminated from the labeling process.
The purification system can be reused for 100+ times
without altering its performance. However tomaintain steril-
ity it is recommended to be used once and disposed.
3.3. MAA Labeling. Labeling yield of MAA with unpurified
68Ga was 78.3 ± 3.1% after 15 minutes at 75∘C, similar to
that reported by other investigators [4]. A labeling yield of
72.1 ± 6.2% was obtained at 50∘C (Figure 4). Better labeling
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Figure 4: 68Ga-MAA labeling yield results.
yield (96.9±2.1%) was obtained at 95∘C; however the particle
quality control showed important changes. Smaller particles
were detected and in higher concentration, apparently due to
the rupture of bigger macroaggregates. The labeling yield at
room temperature was 50 ± 4%. Radiochemical purity tests
were conducted for all the products showing more than 97%
“in vitro” stability in all cases after 4 hours.
The introduction of the 68Ga purification system
improved the labeling yield significantly (𝑃 < 0.003). An
84.1 ± 3.1% labeling yield was obtained at room temperature
(25∘C).This yield is higher than the maximum yield obtained
at 75∘C with unpurified 68Ga. However, if room temperature
labeling is performed, postlabeling purification is still needed
to assure a final radiochemical purity >90%. In the particular
case of MAA, labeling at up to 75∘C has been proven to
not damage the particles. Nevertheless, synthesis near room
temperature or elimination of the heating step all together
is obviously desirable. Good labeling yield of 92.8 ± 2.6%
was obtained at 50∘C. When labeling at this temperature,
purification is still recommended since nearly 10% of free
68Ga will be present in the final product.
The labeling of MAA with purified 68Ga yielded the best
results at 75∘C (Figure 4). A labeling yield of 97.6 ± 1.5% was
obtained after 15 minutes of reaction. Particle distribution
and morphology remained well within specifications and a
>95% radiochemical purity was obtained. Labeling at this
temperature eliminates the need for a purification step,
rendering the final product ready for injection immediately.
Experiments with purified 68Ga-MAA at 95∘C were not
performedbecause of the previously observed particle change
at that temperature.
Relyophilized MAA labeling with purified 68Ga showed
no significant difference from the results obtained with the
washed MAA (𝑃 > 0.8). The elimination of the free albumin
and the stannous chloride from the original formulation fol-
lowed by relyophilization of the MAA does not compromise
either resuspension or morphology (and size distribution)
of the particles. The relyophilized MAA (or MAA prepared
without SnCl
2
and free albumin), in combination with the
68Ga purification system, allows for the preparation of a
single-use lyophilized kit for the preparation of 68Ga-MAA.
This kit can be used for Positron Emission Tomography in
lung perfusion studies, selective internal radiation treatment
(for liver cancer) planning, and other applications requiring
perfusion imaging.
Since terminal studies were conducted, sterility of the
final product was not a concern. However sterility of the
final product is very important to have a successful kit.
To maintain 68Ga-MAA sterility, 68Ga needs to be filtered
through a 0.22𝜇m filter before labeling. In the same way, the
MAA kit must be produced albumin and SnCl
2
free for 68Ga
labeling and its sterility must be guaranteed. Final product
sterility cannot be assured by filtration (since MAA particles
are in the 𝜇mrange); therefore a parametric release is needed.
All labeling procedures for human use must be conducted in
a clean room.
3.4. Animal Experiments. More than 90% of the injected
68Ga-MAA activity was detected in the lungs after tail vein
injection (seen in the image taken after 10 minutes, not
shown) and until at least 4 hours after injection (Table 1). Less
than 2% of ID/o activity was measured in any organ other
than lungs after 2 and 4 hours. Most of the free 68Ga (>60%)
remains in the blood after 4 hours (presumably as 68Ga-native
transferrin complex). The remaining activity was extracted
by the kidneys to the bladder (13%) or absorbed by the liver
(15%). The in vivo radiochemical purity of 68Ga-MAA was
greater than 97% during the studied period.
The behavior and “in vivo” radiochemical purity
of 99mTc-MAA was different than that of 68Ga-MAA.
99mTc was slowly released from the MAA and extracted
by the kidneys into the urine (7.6 ± 1.3 after 2 hours and
12.3 ± 1.2 after 4 hours). Only 86.6 ± 0.7% of the decay
corrected activity was found in the lungs after 2 hours,
decreasing to 79.2 ± 1.5% at 4 hours.
Hydrolyzed 99mTc (reducedwith SnCl
2
) allocatesmainly
in the lungs and liver. The % ID/o did not change over the
study period. 68Ga-MAA exhibited better “in vivo” stability
than 99mTc-MAA (Table 1 and Figure 5). The autoradiogra-
phy images clearly showed the preferential allocation of 68Ga-
MAA in the lungs over the period studied (Figure 6). The
drug-product in-vivo half-life was determined using regions
of interest in the autoradiography images. A square cell of
40 × 40mmwas used to count the activity in the lung region
for each time point (Figure 6). For 99mTc-MAA biological
half-live was found to be 𝑇
1/2
= 11.4 ± 1.7 hours. This is
consistent with the previously reported value of 11.5±4 hour
biological half-life [12]. The biological half-life of 99mTc-
MAA is not to be confused with the MAA biological half-
life. These are equal only if 100% “in vivo” radiochemical
International Journal of Molecular Imaging 5
Table 1: Decay corrected organ biodistribution (DC-ID/o) of 68Ga-MAA, free 68Ga, 99mTc-MAA, and hydrolyzed 99mTc.
Organ Free
68Ga 68Ga-MAA 99mTc-MAA Hydrolyzed 99mTc
2 hours 4 hours 2 hours 4 hours 2 hours 4 hours 2 hours 4 hours
Spleen 0.6 ± 0.5 1.6 ± 0.1 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 7.2 ± 1.1 11.8 ± 0.7
Blood 84.9 ± 4.5 63.1 ± 3.9 0.8 ± 0.8 0.8 ± 0.0 0.9 ± 0.2 0.9 ± 0.0 1.3 ± 1.2 0.4 ± 0.0
Rib 0.5 ± 0.4 1.3 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
Urine 6.8 ± 2.9 14.0 ± 1.7 0.1 ± 0.0 0.1 ± 0.0 7.6 ± 1.3 12.3 ± 1.2 6.1 ± 4.0 0.6 ± 0.2
Right kidney 0.5 ± 0.5 1.6 ± 0.4 0.0 ± 0.0 0.0 ± 0.0 2.1 ± 0.1 3.3 ± 0.1 0.6 ± 0.1 0.4 ± 0.0
Left kidney 0.5 ± 0.5 1.4 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 2.2 ± 0.2 3.4 ± 0.2 0.6 ± 0.1 0.4 ± 0.0
Heart 0.7 ± 0.7 1.5 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
Lungs 3.1 ± 2.9 8.4 ± 0.3 98.6 ± 0.7 98.6 ± 0.1 86.6 ± 0.7 79.2 ± 1.5 39.5 ± 1.5 45.2 ± 10.9
Liver 2.3 ± 1.9 7.2 ± 1.2 0.4 ± 0.2 0.4 ± 0.1 0.5 ± 0.0 0.9 ± 0.0 44.6 ± 2.8 40.9 ± 11.7
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Figure 5:Normalized and radio-decay-corrected lung allocation for
68Ga-MAA and 99mTc-MAA at 1, 2, 3, and 4 hours (𝑛 = 2 per time
point).
purity of 99mTc-MAA is assumed. The assumption was rein-
forced by the fact that injected hydrolyzed 99mTc behaves
differently than that released from the MAA (Table 1 and
Figure 6). The only feasible explanation is that injected
hydrolyzed 99mTc forms nanocolloids with the SnCl
2
, being
absorbed by the liver and lungs, while 99mTc released from
the MAA is quickly absorbed by the kidneys. Furthermore, it
is very unlikely that some form of degraded 99mTc-albumin
will be absorbed by the kidneys for excretion rather than be
degraded in the liver. For over 40 years MAA half-life was
considered to be in the 6–12-hour range [1, 12]. However if
MAA half-life happened to be so short, degradation would
have been observed in the 68Ga-MAA experiments. The
stronger 68Ga-MAAbinding, with superior “in vivo” stability,
proves that MAA half-life is much longer than previously
assumed [9].
The assumption of a shorterMAA half-life (MAA biolog-
ical decomposition) has little or no implication in lung perfu-
sion studies or probe guided surgery. However questionable
implication is present when using the radiolabeled MAA
in planning for liver cancer SIRT. The radio-microsphere
technique is based on several planning steps. One of them is
a particle distribution assessment using 99mTc-MAA, mainly
to determine lung and gastrointestinal (GI) allocation after
hepatic artery injection. If only liver allocation is found
(less than 20% lung allocation and no GI allocation), then
the radio-microsphere treatment is administered after 48
hours since the MAA is assumed to have been cleared
from the vessels (assuming a MAA half-life of 6–12 hours).
Despite this wrong assumption, the treatment is successful.
Therefore, it must be concluded that the effectiveness of
the treatment does not require the complete decay of the
treatment planning microparticles. Because they are injected
in small numbers, enough arterioles seem to still be available
for the allocation of the therapy particles. However, whether
or not the treatment could benefit from the use of fast
degrading planning particles (faster than MAA) remains
an open question. Nevertheless, a precise determination of
MAA half-life is needed and can probably be measured
by combining the strong gallium binding with a longer
radioactive half-life (e.g., 67Ga-MAA).
The relyophilization of washedMAAwas a first approach
to show the feasibility of a lyophilized kit specifically for 68Ga-
MAA. In a production facility the pharmaceutical develop-
ment would need to be different from that of the 99mTc-
MAA kit. Free albumin and SnCl
2
would not need to be
added to the final product. The high labeling yield obtained
during the preparation of 68Ga-MAA eliminates the need for
final centrifugation for purification. What seems to be the
apparent elimination of a single step has major implications.
In these conditions the purification/labeling scheme can be
easily automated using one of the available modular labs for
PET synthesis (e.g., Modular-Lab PharmTracer, Eckert and
Ziegler, Germany), or it could easily be accomplished in a
nuclear medicine hot-lab in a hospital.
4. Conclusions
A Gallium specific lyophilized kit for 68Ga-MAA production
was created. The kit is comprised of a vial containing MAA
(relyophilized DraxImage kit), a 68Ga purification system,
6 International Journal of Molecular Imaging
Free 68Ga MAA-68Ga MAA-99mTc Hydrolyzed 99mTc
𝛾 counts
counts
1
ho
ur
2
ho
ur
3
ho
ur
4
ho
ur
X-ray
Figure 6: Non decay-corrected, uncollimated full body autoradiography for free 68Ga (𝑇
1/2
= 68min), 68Ga-MAA, 99mTc-MAA, and
hydrolyzed 99mTc (𝑇
1/2
= 6.02 h) at 1, 2, 3, and 4 hours. Labeling of 68Ga-MAA was performed with relyophilized MAA and purified 68Ga at
75∘C for 15 minutes. The autoradiograph is superimposed on an X-ray image of the same animal in the unaltered supine position.
andworking solutions in the following syringes: 5mLof 0.1M
HCl (elution), 1mL 0.1 of M HCl (cleaning), 1mL of 5M
HCl (purification), 1mL of Millipore water (extraction), and
0.3mL of 3NNaAc solution (buffer).The purification system
can also be used for labeling of most 68Ga imaging agents
(e.g., DOTANOC and DOTATOC) with a small variation
in the buffer amount. Labeling of MAA at 75∘C for 15
minutes is recommended for labeling yields higher than 95%
with no further purification necessary. Room temperature
labeling is possible for producing 80% labeling yield but
postlabeling purification is needed. Lung perfusion PET
images are recommended to be acquired within the first
hour after injection because of the short half-life of the
68Ga. The “in vivo” stability of the obtained 68Ga-MAA drug
product is superior to that of 99mTc-MAA. Use of 68Ga-
MAA in SIRT planning is also possible, likely to benefit
from superior imaging/quantification and more accurate
dosimetric calculations.
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MAA: Macroaggregated albumin
PET: Positron Emission Tomography
SIRT: Selective Internal Radiation Treatment
SPECT: Single Photon Emission Tomography.
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